Cardinal Health Inc
Q1 2026 Earnings
Market Reaction
S&P 500 over the same 30 days: +0.25%.
Did CAH Beat Earnings? Q1 2026 Results
Cardinal Health kicked off fiscal 2026 with a decisive beat on both the top and bottom lines, as the healthcare distribution giant reported first-quarter revenue of $64.01 billion, up 22.4% year-over-year and ahead of the $59.27 billion consensus by 8.00%, while non-GAAP diluted EPS of $2.55 cleared the $2.17 analyst estimate by 17.33%. The primary engine behind the outperformance was the Pharmaceutical and Specialty Solutions segment, where revenue climbed 23% to $59.20 billion and segment profit rose 26% to $667.00 million, fueled by robust brand and specialty pharmaceutical sales, positive generics program performance, and contributions from MSO platform acquisitions. The Global Medical Products and Distribution segment also turned a meaningful corner, with segment profit jumping to $46.00 million from just $8.00 million a year earlier. Management responded to the strong results by raising full-year non-GAAP EPS guidance to $9.65 to $9.85, representing 17% to 20% growth, while investors are weighing whether the stock's sharp post-earnings appreciation has pulled valuation ahead of fundamentals.
- Brand and specialty pharmaceutical sales growth from existing and new customers
- Positive generics program performance
- Contributions from MSO platform acquisitions
- Advanced Diabetes Supply acquisition contributing to at-Home Solutions growth
- Volume growth from existing customers in GMPD
- Lower share count and lower effective tax rate boosting non-GAAP EPS
- Growth across all five operating segments
“We are pleased with our strong broad-based operational and financial performance to begin fiscal 2026. This outstanding first quarter reflects our focused execution across each of our operating segments and provides a solid foundation as we carry forward. As a result, we are raising our fiscal 2026 outlook.”
Cardinal Health CEO, on the earnings call
Forward Guidance & Outlook
Cardinal Health raised its fiscal year 2026 non-GAAP diluted EPS guidance to $9.65–$9.85 (up from $9.30–$9.50), representing 17%–20% growth. The company also raised its non-GAAP adjusted free cash flow outlook to $3.0–$3.5 billion (from $2.75–$3.25 billion). Pharmaceutical and Specialty Solutions segment profit growth guidance was raised to 16%–19% (from 11%–13%), and Other segment profit growth was raised to 29%–31% (from 25%–27%). Updated assumptions include interest and other expense of ~$325 million (from ~$275 million, reflecting Solaris Health financing), diluted weighted average shares of ~238 million, and capital expenditures of $600–$650 million. The company expects to complete the Solaris Health acquisition in early November.
CAH YoY Financials
CAH Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.